Related Experiment Video
Updated: Aug 15, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Pathogenesis and treatment of the antiphospholipid antibody syndrome
1Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Antiphospholipid antibody syndrome (APS) is one of the most important causes of thrombophilia, presenting most often as venous or arterial thrombosis, recurrent pregnancy loss, or thrombocytopenia. Both the lupus anticoagulant and anticardiolipin antibody are associated with APS. The mechanism of the prothrombotic state is not understood, but may involve beta-2 glycoprotein 1 (a naturally occurring anticoagulant), platelet aggregation, the protein C pathway, or endothelial cell function. The current treatment recommendation, after a venous or arterial thrombosis, is high-intensity, long-term warfarin therapy.
Antiphospholipid antibody syndrome (APS) is one of the most important causes of thrombophilia, presenting most often as venous or arterial thrombosis, recurrent pregnancy loss, or thrombocytopenia. Both the lupus anticoagulant and anticardiolipin antibody are associated with APS. The mechanism of the prothrombotic state is not understood, but may involve beta-2 glycoprotein 1 (a naturally occurring anticoagulant), platelet aggregation, the protein C pathway, or endothelial cell function. The current treatment recommendation, after a venous or arterial thrombosis, is high-intensity, long-term warfarin therapy.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Atherosclerosis III: Management
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

